Despite significant progress and improving outcomes in the management of plasma cell
disorders, AL amyloidosis remains diagnostically and therapeutically challenging for …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Cardiac amyloidosis (CA) refers to an infiltrative process involving amyloid fibril deposition
in the myocardium causing restrictive cardiomyopathy. While various types can affect the …

Background Advancements in treatment regimens have led to improved outcomes in renal
Immunoglobulin light-chain amyloidosis. Nevertheless, a subset of patients may still …

Background Amyloid light chain (AL) amyloidosis is the most common systemic amyloidosis.
The objective of this scoping review was to map the available literature on the diagnosis of …

Simple Summary Light-chain (AL) amyloidosis is a rare disease similar to the more common
disease, multiple myeloma (MM). Both are caused by proliferation of malignant plasma cells …

Introduction Light chain (AL) amyloidosis is a rare and complex disease which can affect
various systems of the body. In common with many rare and multisystemic diseases, the …

(1) Background: To evaluate the predictive value of Holter monitoring for overall survival
(OS) of patients with light chain amyloidosis (AL amyloidosis).(2) Methods: 137 patients with …

Primary systemic amyloidosis is generally a systemic condition and only a few of systemic
amyloidosis cases manifest with signs of single-organ involvement. The occurrence of …

Introduction Immunoglobulin light chain (AL) amyloidosis presents a clinical spectrum
characterized by diverse manifestations and involvement of multiple organs, posing a …